{
  "source": "PA-Notification-Erleada.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1244-8\nProgram Prior Authorization/Notification\nMedication Erleada® (apalutamide)\nP&T Approval Date 5/2018, 5/2019, 11/2019, 11/2020, 11/2021, 11/2022, 11/2023, 11/2024\nEffective Date 2/1/2025\n1. Background:\nErleada (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with\nnon-metastatic castration-resistant prostate cancer. It is also indicated for the treatment of\nmetastatic castration-sensitive prostate cancer. Patients should also receive a gonadotropin-\nreleasing hormone (GnRH) analog concurrently while taking Erleada or should have had bilateral\norchiectomy.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the notification\ncriteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Erleada will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Prostate Cancer\n1. Initial Authorization\na. Erleada will be approved based on all of the following criteria:\n(1) Diagnosis of prostate cancer\n-AND-\n(2) One of the following:\n(a) Both of the following:\n© 2024 UnitedHealthcare Services, Inc.\n1\ni. Disease is castration-resistant or recurrent\n-AND-\nii. Disease is non-metastatic\n-OR-\n(b) Both of the following:\ni. Disease is castration-sensitive or naive\n-AND-\nii. Disease is metastatic\n-AND-\n(3) One of the following:\n(a) Used in combination with a gonadotropin-releasing hormone (GnRH)\nanalog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin),\nVantas ",
    " metastatic\n-AND-\n(3) One of the following:\n(a) Used in combination with a gonadotropin-releasing hormone (GnRH)\nanalog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin),\nVantas (histrelin), Firmagon (degarelix)]\n-OR-\n(b) Patient has had bilateral orchiectomy\nAuthorization will be issued for 12 months.\n2. Reauthorization Criteria\na. Erleada will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Erleada therapy\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n2\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Erleada [package insert]. Horsham, PA: Janssen Products LP; August 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at NCCN\nDrugs and Biologics Compendium®. Accessed October 8, 2024.\nProgram Prior Authorization/Notification – Erleada (apalutamide)\nChange Control\n5/2018 New program\n5/2019 Annual review with no change to coverage criteria. Updated reference.\n11/2019 Updated background and criteria to include new labeled indication in\nmetastatic castration-sensitive prostate cancer. Added general NCCN\nrecommendations for use s",
    " criteria. Updated reference.\n11/2019 Updated background and criteria to include new labeled indication in\nmetastatic castration-sensitive prostate cancer. Added general NCCN\nrecommendations for use statement. Updated references.\n11/2020 Annual review. Minor formatting change. Updated references.\n11/2021 Annual review with no change to coverage criteria. Updated references.\n11/2022 Annual review with no changes to clinical coverage criteria. Updated\nreference and added state mandate footnote.\n11/2023 Annual review with no change to coverage criteria. Updated references.\n11/2024 Annual review with no change to coverage criteria. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}